Tangen wins contract for Candida auris point-of-care test

2020 06 29 18 19 9989 Lb 2020 06 29 Tangen Gene Spark Instrument 400

Tangen Biosciences has won a contract with the New York State Department of Health's Wadsworth Center, a large public health laboratory, to develop a rapid skin swab test for the treatment-resistant fungus Candida auris.

The C. auris test will run on the company's TangenDx platform, which includes an assay kit and the company's GeneSpark analyzer. Tangen currently markets rapid tests for bloodstream Candida infections, bacterial infections, and antimicrobial resistance. It plans to file an emergency use authorization for a point-of-care COVID-19 test with the U.S. Food and Drug Administration this summer.

Page 1 of 3
Next Page